ArticleTransgender health2025
The Utility of Serum Free Testosterone Concentrations in Monitoring Gender-Affirming Testosterone Therapy in Transmasculine Youth with Obesity.
Article in Transgender health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to explore the use of serum free testosterone concentrations in transmasculine patients as a more reliable indicator of gender-affirming testosterone therapy than total testosterone concentration. Total testosterone values, recommended by current guidelines, may be impacted by obesity. In addition, this study aimed to characterize the impact of testosterone concentrations on hematocrit and the risk of polycythemia. Methods: A retrospective study was conducted of transmasculine patients seen at Boston Children's Hospital Gender Multispecialty Service from 2007 to 2020. Sixty-eight birth-assigned female adolescents who were receiving gender-affirming testosterone therapy and had total and free testosterone concentrations were included. The aims were to determine the fidelity of total and free testosterone concentrations with body mass index (BMI) and to characterize the association of testosterone concentrations with erythrocytosis. Results: Of 68 subjects, 23% were overweight and 40% had obesity. Compared with the group with a healthy BMI, patients with obesity had significantly lower total testosterone concentrations. Free testosterone concentrations did not vary based on BMI category. BMI z-score was inversely correlated with total testosterone, sex hormone-binding globulin, and albumin concentrations but not with free testosterone concentrations. Four percent of subjects developed erythrocytosis (e.g., hematocrit >50%). Neither BMI nor testosterone concentrations were correlated with hematocrit. Conclusions: Free testosterone concentrations are an adjunctive tool in the monitoring of gender-affirming testosterone therapy. In addition, the development of erythrocytosis is independent of serum testosterone concentration and warrants further study to understand factors that may predispose patients to developing secondary polycythemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.